Abstract:Background: Irinotecan (CPT-11) is a classic chemotherapeutic agent that plays an important role in the clinical treatment of metastatic colon cancer and other malignant tumors. We previously designed a series of novel irinotecan derivatives. In this study, we select one representative, ZBH-01, to investigate its sophisticated antitumor mechanism in colon tumor cells. Methods: The cytotoxic activity of ZBH-01 on colon cancer cells was evaluate by MTT or Cell Counting Kit-8 (CCK8) assay, 3D and xenograft model. The inhibitory effect of ZBH-01 on TOP1 was detected by DNA relaxation assay and Immuno Complex of Ezyme (ICE) bioassay. The molecular mechanism of ZBH-01 was explored by Next-Generation Sequencing (NGS), bioinformatics analyses, flow cytometry, qRT-PCR, and western blot etc. RESULTS: ZBH-01 can induce obvious DNA damage and has superior antitumor activity against colon cancer cells compared to CPT-11 and SN38 (7-Ethyl-10-hydroxy camptothecin, the in vivo active form of CPT-11) both in vivo and in vitro. Its inhibitory effect on topoisomerase I (TOP1) was also comparable with these two control drugs. There are a much larger number of 842 downregulated and 927 upregulated mRNAs in ZBH-01 treatment group than that in the controls. The most significantly enriched KEGG pathways for these dysregulated mRNAs were DNA replication, the p53 signaling pathway, and the cell cycle. After constructing a protein-protein interaction (PPI) network and screening out a prominent cluster, 14 involved in the cell cycle process was identified. Consistently, ZBH-01 induced G0/G1 phase arrest in colon cancer cells, while CPT-11/SN38 caused S phase arrest. The initiation of apoptosis by ZBH-01 was also superior to CPT-11/SN38, followed by the increased expression of Bax, active caspase 3, and cleaved-PARP, and decreased expression of Bcl-2. Additionally, CCNA2 (cyclin A2), CDK2 (cyclin-dependent kinase 2), and MYBL2 (MYB proto-oncogene like 2) might be involved in the G0/G1 cell cycle arrest induced by ZBH-01. Conclusions: ZBH-01 can be an antitumor candidate drug for preclinical study in the future.

Design, Synthesis and Pharmacological Evaluation of a Novel PEG-cRGD-conjugated Irinotecan Derivative As Potential Antitumor Agent.

Design, Synthesis and Antitumor Activity of a Novel PEG-A6-conjugated Irinotecan Derivative.

Design and Synthesis of Novel PEG-conjugated 20(S)-Camptothecin Sulfonylamidine Derivatives with Potent in Vitro Antitumor Activity Via Cu-catalyzed Three-Component Reaction

Full-profile Pharmacokinetics, Anticancer Activity and Toxicity of an Extended Release Trivalent PEGylated Irinotecan Prodrug

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Design, Synthesis and Pharmacological Evaluation of Β-Carboline Derivatives As Potential Antitumor Agent Via Targeting Autophagy

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle

Study on anti-tumor activity and mechanism of novel Irinotecan derivatives ZBH-1208 in vitro

Irgd-Functionalized PEGylated Nanoparticles for Enhanced Colon Tumor Accumulation and Targeted Drug Delivery

Design and synthesis of novel 20(S)-α-aminophosphonate derivatives of camptothecin as potent antitumor agents

TQ-B3203, a Potent Proliferation Inhibitor Derived from Camptothecin

A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer

Synthesis, Mechanisms of Action, and Toxicity of Novel Aminophosphonates Derivatives Conjugated Irinotecan in Vitro and in Vivo As Potent Antitumor Agents.

A Novel Irinotecan Derivative ZBH-1207 with Different Anti-Tumor Mechanism from CPT-11 Against Colon Cancer Cells.

Irinotecan Delivery by Unimolecular Micelles Composed of Reduction-Responsive Star-Like Polymeric Prodrug with High Drug Loading for Enhanced Cancer Therapy.

Design, Synthesis, and Cytotoxic Activity of Novel 7-Substituted Camptothecin Derivatives Incorporating Piperazinyl-Sulfonylamidine Moieties.

Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine

Synthesis of [3Β-Acetoxy-urs-12-en-28-oyl]-1-monoglyceride and Investigation on Its Anti Tumor Effects Against BGC-823.

Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs

(E)-N-Aryl-2-oxo-2-(3,4,5-trimethoxyphenyl)acetohydrazonoyl cyanides as tubulin polymerization inhibitors: Structure-based bioisosterism design, synthesis, biological evaluation, molecular docking and in silico ADME prediction.